GET DAILY SIGNALSALLO vs EDIT: Weighing Allogene Therapeutics and Editas Medicine
Key Takeaways
- Both ALLO and EDIT are clinical-stage biotechnology companies with no approved products, making their stock narratives driven almost entirely by pipeline data and cash runway.
- Allogene is advancing "off-the-shelf" CAR T (chimeric antigen receptor T-cell) therapies, led by cema-cel in a pivotal Phase 2 lymphoma study, while Editas is pivoting toward in vivo (inside-the-body) gene editing led by EDIT-401 for high cholesterol.
- Allogene reported a strong interim MRD (minimal residual disease) negativity signal of 58.3% versus 16.7% for observation, while Editas secured Australian clearance to begin its first human trial of EDIT-401.
- Both stocks have rallied year-to-date but pulled back sharply in recent weeks, reflecting the volatile, catalyst-driven nature of early-stage biotech equities.
- Allogene's cash runway extends into 2029, whereas Editas projects funding into the second half of 2028, giving Allogene a somewhat longer financial cushion.
- For more detail on key developments and intraday activity, explore ALLO Major News and ALLO Today's Price Move, as well as EDIT Major News and EDIT Today's Price Move.
- Interested in how automated systems are positioning across these and other names? Explore Trending AI Robots for a curated view of top-performing strategies.
Setting the Stage
Allogene Therapeutics (ALLO) and Editas Medicine (EDIT) sit at the intersection of two of biotechnology's most closely watched frontiers: engineered cell therapy and CRISPR gene editing. Neither company yet generates meaningful product revenue, so their valuations hinge on clinical catalysts, trial readouts, and balance-sheet durability. This comparison is most relevant to growth-oriented and event-driven investors who track high-risk, high-reward biotech names and want to understand how relative performance, pipeline positioning, and market sentiment differ between two development-stage leaders.
Allogene's Position and Recent Moves
Allogene Therapeutics develops allogeneic, or "off-the-shelf," CAR T-cell therapies for cancer and autoimmune disease. Unlike autologous treatments that use a patient's own cells, Allogene's platform uses healthy donor cells engineered for broader availability and faster treatment. Its lead program, cema-cel, is in the pivotal Phase 2 ALPHA3 study in large B-cell lymphoma, with an interim futility analysis showing 58.3% MRD negativity at day 45 versus 16.7% for observation. The company also advanced ALLO-329 into a Phase 1 study across autoimmune conditions. After a public offering raised roughly $200 million, Allogene reported approximately $423.6 million in cash and investments as of mid-2026, supporting a runway into 2029. Despite strong year-to-date gains, shares pulled back notably in recent weeks, reflecting profit-taking and sector-wide volatility following a period of positive clinical momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Editas' Developments and Recent Moves
Editas Medicine is a pioneer in CRISPR-based gene editing. Following the late-2024 discontinuation of its reni-cel program and a roughly 65% workforce reduction, the company refocused on in vivo editing. Its lead candidate, EDIT-401, is a one-time therapy designed to edit the LDLR gene and durably lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, an inherited condition linked to elevated cardiovascular risk. In recent weeks, Editas received Australian regulatory clearance to begin its Phase 1/2 Strive trial, its first human study of EDIT-401, supported by preclinical data showing roughly 90% reductions in atherogenic lipoproteins. The company reported approximately $211.6 million in cash and investments, with a runway into the second half of 2028. Shares climbed year-to-date before easing in recent trading, with analysts highlighting 2027 as a potential inflection point. From what I see, this pivot represents a meaningful shift in focus.
Head-to-Head Comparison
The two companies differ sharply in therapeutic focus and maturity. Allogene targets oncology and autoimmune disease through cell therapy, with a lead program already in a pivotal study and multiple near-term data readouts on the horizon. Editas is effectively at a preclinical-to-early-clinical transition, betting on a single in vivo program in cardiovascular disease. In terms of growth drivers, Allogene's value rests on translating promising MRD data into a durable event-free survival signal, while Editas's hinges on early human safety and efficacy results for EDIT-401. Risk profiles also diverge: Allogene carries clinical and manufacturing-scale risks across a broader pipeline but holds a longer cash runway, while Editas faces concentrated single-asset risk and earlier-stage uncertainty, with a shorter runway. Sector exposure overlaps in biotechnology, yet momentum has favored whichever company delivers the most recent catalyst, underscoring the event-driven nature of both names.
AI Insights on the Pair
Based on observable factors such as trend consistency, balance-sheet durability, and the maturity of clinical catalysts, Tickeron's AI would likely view ALLO as holding a modest relative edge in the current environment. A later-stage pivotal program, a longer cash runway, and a broader pipeline of near-term readouts provide a comparatively steadier catalyst path. EDIT carries meaningful upside potential tied to its first-in-human data, but that potential is more concentrated and earlier-stage, introducing greater variability. This assessment is probabilistic rather than definitive, reflecting the inherent uncertainty of clinical-stage investing rather than a recommendation to buy or sell either security.
Exploring AI Trading Strategies
I often turn to Tickeron’s Trending AI Robots to see which automated strategies are gaining traction in volatile names like these. The page highlights a curated selection of AI trading bots suited to current conditions, spanning different styles, timeframes, and risk profiles. Reviewing this section gives useful context on how algorithms are positioning across biotech and other sectors right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.037). P/E Ratio (-3.939) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement